Loading...
XJPX4587
Market cap2.10bUSD
Dec 26, Last price  
2,561.00JPY
1D
-0.85%
1Q
-5.83%
Jan 2017
-15.76%
IPO
122.70%
Name

PeptiDream Inc

Chart & Performance

D1W1MN
XJPX:4587 chart
P/E
109.34
P/S
11.56
EPS
23.42
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
31.81%
Revenues
28.71b
+6.93%
269,004,000678,269,000818,901,0002,474,499,0004,327,878,0004,895,747,0006,426,891,0007,216,622,0002,074,674,00011,677,253,0009,365,964,00026,852,430,00028,712,194,000
Net income
3.04b
-59.81%
9,971,000137,180,000148,512,0001,004,164,0001,581,288,0001,890,750,0002,335,216,0002,770,141,000-976,928,0004,448,357,0003,606,407,0007,554,358,0003,035,832,000
CFO
12.42b
P
-150,484,000234,566,00072,174,0001,386,143,0001,533,057,0001,530,776,0001,022,716,0004,480,938,000241,982,0001,732,733,0006,654,708,000-82,929,00012,420,969,000
Earnings
Feb 12, 2025

Profile

PeptiDream Inc., a biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics. The company develops its products based on its Peptide Discovery Platform System, a drug finding platform for the development of peptides. It has a collaborative research and exclusive license agreement with Takeda Pharmaceutical Company Limited to develop peptide drug conjugates for neuromuscular diseases. The company was incorporated in 2006 and is headquartered in Kawasaki, Japan.
URL
https://www.peptidream.com/
IPO date
Jun 11, 2013
Employees
692
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122019‑062018‑062017‑062016‑062015‑06
Income
Revenues
28,712,194
6.93%
26,852,430
186.70%
9,365,964
-19.79%
Cost of revenue
21,905,561
19,145,678
5,148,416
Unusual Expense (Income)
NOPBT
6,806,633
7,706,752
4,217,548
NOPBT Margin
23.71%
28.70%
45.03%
Operating Taxes
1,317,636
(901,033)
1,217,244
Tax Rate
19.36%
28.86%
NOPAT
5,488,997
8,607,785
3,000,304
Net income
3,035,832
-59.81%
7,554,358
109.47%
3,606,407
-18.93%
Dividends
Dividend yield
Proceeds from repurchase of equity
(514,554)
(167)
44,578
BB yield
0.27%
0.00%
-0.01%
Debt
Debt current
1,402,274
2,690,653
(244,063)
Long-term debt
19,957,607
18,706,029
Deferred revenue
(1,077,808)
Other long-term liabilities
476,932
2,435,535
(174,687)
Net debt
(10,036,497)
9,627,075
(18,128,686)
Cash flow
Cash from operating activities
12,420,969
(82,929)
6,654,708
CAPEX
(1,368,962)
(3,975,416)
(1,214,678)
Cash from investing activities
1,302,539
(27,377,217)
(2,283,450)
Cash from financing activities
264,191
20,789,451
66,067
FCF
14,788,919
(13,958,502)
5,515,109
Balance
Cash
19,514,106
5,253,908
11,746,529
Long term investments
11,882,272
6,515,699
6,138,094
Excess cash
29,960,768
10,426,986
17,416,325
Stockholders' equity
36,884,194
28,124,362
22,710,083
Invested Capital
33,342,566
41,695,626
7,120,997
ROIC
14.63%
35.27%
37.18%
ROCE
10.69%
14.49%
16.83%
EV
Common stock shares outstanding
129,841
129,935
129,926
Price
1,486.50
-28.43%
2,077.00
-18.39%
2,545.00
-51.43%
Market cap
193,009,084
-28.48%
269,876,023
-18.38%
330,661,558
-51.40%
EV
182,972,587
279,503,098
312,532,872
EBITDA
9,239,815
9,680,131
4,850,554
EV/EBITDA
19.80
28.87
64.43
Interest
2,253,012
2,312,643
Interest/NOPBT
33.10%
30.01%